Compass Therapeutics (CMPX) Cash from Investing Activities (2023 - 2026)
Compass Therapeutics' Cash from Investing Activities history spans 4 years, with the latest figure at $38.4 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 231.63% to $38.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$66.5 million, a 206.41% decrease, with the full-year FY2025 number at -$93.3 million, down 299.49% from a year prior.
- Cash from Investing Activities hit $38.4 million in Q1 2026 for Compass Therapeutics, up from -$3.4 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for CMPX hit a ceiling of $38.4 million in Q1 2026 and a floor of -$95.2 million in Q3 2025.
- Historically, Cash from Investing Activities has averaged $1.5 million across 4 years, with a median of $6.3 million in 2023.
- Biggest five-year swings in Cash from Investing Activities: skyrocketed 1071.96% in 2024 and later crashed 427.92% in 2025.
- Tracing CMPX's Cash from Investing Activities over 4 years: stood at $6.3 million in 2023, then soared by 143.43% to $15.4 million in 2024, then crashed by 121.98% to -$3.4 million in 2025, then soared by 1237.63% to $38.4 million in 2026.
- Business Quant data shows Cash from Investing Activities for CMPX at $38.4 million in Q1 2026, -$3.4 million in Q4 2025, and -$95.2 million in Q3 2025.